| Rescuing over-activated microglia restores cognitive performance in juvenile animals of the Dp (16) mouse model of Down syndrome B Pinto, G Morelli, M Rastogi, A Savardi, A Fumagalli, A Petretto, ... Neuron 108 (5), 887-904. e12, 2020 | 84 | 2020 |
| Discovery of a small molecule drug candidate for selective NKCC1 inhibition in brain disorders A Savardi, M Borgogno, R Narducci, G La Sala, JA Ortega, M Summa, ... Chem 6 (8), 2073-2096, 2020 | 52 | 2020 |
| Pharmacological tools to target NKCC1 in brain disorders A Savardi, M Borgogno, M De Vivo, L Cancedda Trends in pharmacological sciences 42 (12), 1009-1034, 2021 | 37 | 2021 |
| In vivo methods for acute modulation of gene expression in the central nervous system AW Cwetsch, B Pinto, A Savardi, L Cancedda Progress in neurobiology 168, 69-85, 2018 | 26 | 2018 |
| APache is an AP2-interacting protein involved in synaptic vesicle trafficking and neuronal development A Piccini, E Castroflorio, P Valente, FC Guarnieri, D Aprile, C Michetti, ... Cell Reports 21 (12), 3596-3611, 2017 | 16 | 2017 |
| Design, Synthesis, In Vitro and In Vivo Characterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Down Syndrome M Borgogno, A Savardi, J Manigrasso, A Turci, C Portioli, G Ottonello, ... Journal of medicinal chemistry 64 (14), 10203-10229, 2021 | 15 | 2021 |
| A rat model of a focal mosaic expression of PCDH19 replicates human brain developmental abnormalities and behaviours AW Cwetsch, I Ziogas, R Narducci, A Savardi, M Bolla, B Pinto, LE Perlini, ... Brain Communications 4 (3), fcac091, 2022 | 6 | 2022 |
| Preclinical development of the Na-K-2Cl co-transporter-1 (NKCC1) inhibitor ARN23746 for the treatment of neurodevelopmental disorders A Savardi, A Patricelli Malizia, M De Vivo, L Cancedda, M Borgogno ACS Pharmacology & Translational Science 6 (1), 1-11, 2023 | 5 | 2023 |
| Selective NKCC1 Inhibitors for the Treatment of Neurodevelopmental and Neurological Disorders with Defective NKCC1/KCC2 expression-ratio (P2-12.003) A Savardi, M Borgogno, M De Vivo, L Cancedda Neurology 100 (17 Supplement 2), 2023 | 1 | 2023 |
| Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target A Potenzieri, S Uccella, D Preiti, M Pisoni, S Rosati, C Lavarello, ... Science Advances 10 (9), eadk8123, 2024 | | 2024 |
| EARLY-IN-LIFE INTERVENTIONS TARGETING NKCC1 RESCUE THE ALTERED GABAERGIC SIGNALING AND THE EPILEPTIC AND LOCOMOTOR DEFICITS IN THE ADULT DS MICE I Colombi, I Ziogas, A Fumagalli, M Parrini, A Savardi, M Alberti, ... IBRO Neuroscience Reports 15, S84, 2023 | | 2023 |
| Modulators of intracellular chloride concentration L Cancedda, DE Marco, A Contestabile, M Borgogno, A Savardi, ... | | 2022 |
| BRAIN COMMUNICATIONS AIN COMMUNICATIONS AW Cwetsch, I Ziogas, R Narducci, A Savardi, M Bolla, B Pinto, LE Perlini, ... | | 2022 |
| Modulators of intracellular chloride concentration L CANCEDDA, DE Marco, A CONTESTABILE, M BORGOGNO, ... | | 2020 |
| The Ion-Transporter NKCC1 as a Target for Brain Diseases C Portioli, A Savardi, Z Ren, M De Vivo, M Zhou, L Cancedda Biophysical Journal 118 (3), 129a, 2020 | | 2020 |
| Chloride transporters in physiological brain development and neurodevelopmental disorders: The case of the Down syndrome A Savardi, I Ziogas, M Bolla, L Cancedda Neuronal Chloride Transporters in Health and Disease, 569-616, 2020 | | 2020 |
| APache Is an AP2-Interacting Protein Involved inSynaptic Vesicle Trafficking and Neuronal Development S Giovedi, F Benfenati, F Valtorta, A Fassio, JD Wren, A Cattaneo, A Bachi, ... Elsevier, 2017 | | 2017 |
